Enzymatica AB logo

Enzymatica AB (EN9)

Market Closed
2 Jun, 20:00
XMUN XMUN
0. 2350
0
0%
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
-0.2 Eps
0.235
Previous Close
Add Transaction
Day Range
0.235 0.235
Year Range
0.1745 0.279
Want to track EN9 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

EN9 closed yesterday higher at €0.23, an increase of 0% from Monday's close, completing a monthly increase of 0% or €0. Over the past 12 months, EN9 stock gained 34.67%.
EN9 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).

EN9 Chart

Enzymatica AB (EN9) FAQ

What is the stock price today?

The current price is €0.2350.

On which exchange is it traded?

Enzymatica AB is listed on XMUN.

What is its stock symbol?

The ticker symbol is EN9.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Enzymatica AB ever had a stock split?

No, there has never been a stock split.

Enzymatica AB Profile

Specialty Retail Industry
Consumer Discretionary Sector
Ms. Sana Alajmovic CEO
XMUN Exchange
SE0003943620 ISIN
SE Country
20 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Enzymatica AB (publ) is a life science company established in 2007, with its headquarters located in Lund, Sweden. The company specializes in developing and marketing products designed to treat and alleviate infections and symptoms in the upper respiratory tract. Enzymatica's business model involves collaborating with contract organizations and engaging in partner agreements with distributors for the sale of its products. These products are sold under various brand names, including ViruProtect, STADAProtect, and Bisolviral, depending on the geographical location and distribution agreement.

Products and Services

  • ColdZyme: This is Enzymatica's flagship product, a mouth spray aimed at treating and alleviating symptoms of cold and flu. ColdZyme is designed to create a protective barrier in the throat against common cold viruses, thereby offering relief from symptoms and possibly shortening the duration of a cold.
  • Enzyme Formulations for Skin Care: In addition to its respiratory products, Enzymatica AB develops enzyme-based formulations for skin care. These products leverage the natural properties of enzymes to promote healthy skin, offering a unique approach to skincare that complements traditional methods.

Contact Information

Address: Ideon Science Park, Lund, Sweden, 223 70
Phone: 46 4 62 86 31 00